ACADIA Pharmaceuticals (ACAD) Stock Price & Analysis
ACAD Stock Chart & Stats
- Day’s Range
- MXN 389.00 - MXN 389.00
- 52-Week Range
- MXN 340.00 - MXN 550.00
- Previous Close
- MXN 355.00
- Volume
- 0
- Average Volume (3M)
- 13
- Market Cap
- MXN 66.67B
- Enterprise Value
- MXN 3.49B
- Total Cash (Recent Filing)
- MXN 956.47M
- Total Debt (Recent Filing)
- MXN 73.85M
- Price to Earnings (P/E)
- 9.2
- Beta
- -0.12
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 3.74
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth
Both marketed products are contributing to growth, reducing reliance on a single commercial asset. DAYBUE is scaling rapidly while NUPLAZID continues to expand through higher volume and prescriptions, supporting durable revenue growth over the next several quarters.
Profitability And Balance Sheet
ACADIA has moved from historical losses to substantial profitability while maintaining very modest leverage. The combination of strong earnings, low debt, and expanding equity provides financial flexibility to fund commercialization, research, and potential business development.
Pipeline And Regulatory Expansion
Regulatory progress for trofinetide can broaden DAYBUE’s geographic opportunity, while the advancing remlifanserin program adds a potential future CNS growth driver. These developments strengthen the company’s product portfolio beyond its current U.S. sales base.
Bears Say
Remlifanserin Efficacy Uncertainty
The primary-endpoint miss increases uncertainty around remlifanserin’s probability of success despite positive secondary-endpoint and safety observations. Continued Phase III development may preserve upside, but equivocal efficacy evidence could delay or reduce the pipeline’s contribution.
Uneven Cash Generation
ACADIA is generating positive cash, but the recent free-cash-flow decline and mixed conversion from reported profits indicate that earnings are not translating consistently into cash. Persistent variability could limit internally funded investment and make operating discipline more important.
Gross-to-net Pressure And Costs
Large deductions from gross sales reduce realized revenue and can pressure margins even while prescriptions grow. At the same time, higher commercial spending raises the cost of maintaining momentum, creating execution risk if sales expansion does not outpace access deductions and operating expense growth.
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
What is ACADIA Pharmaceuticals’s market cap?
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
How were ACADIA Pharmaceuticals’s earnings last quarter?
Is ACADIA Pharmaceuticals overvalued?
Does ACADIA Pharmaceuticals pay dividends?
What is ACADIA Pharmaceuticals’s EPS estimate?
How many shares outstanding does ACADIA Pharmaceuticals have?
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
ACADIA Pharmaceuticals Stock Smart Score
Company Description
ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Catherine E. Owen Adams
- Employees
- 797
- Website
- www.acadia.com
- Address
- 12830 El Camino Real, San Diego, CA, 92130, US
ACADIA Pharmaceuticals (ACAD) Earnings & Revenues
ACAD Company Deck
ACAD Earnings Call
Earnings Call SentimentPositive
The call conveyed strong commercial momentum and clear near-term catalysts: robust Q2 results (total revenues +17%), pronounced DAYBUE STIX uptake (DAYBUE +30% YoY), healthy NUPLAZID growth (+10% YoY) with new prescriptions up 20%, a positive CHMP opinion for trofinetide in Europe, and significant pipeline progress (remlifanserin Phase II enrollment complete, Fast Track designation, top-line data expected Sep–Oct 2026). Offsetting factors include rising SG&A, sizable gross‑to‑net adjustments (~24%), a lowered R&D spend guidance due to a shifted BD milestone, reimbursement and pricing uncertainties in Europe, and dependency on upcoming pivotal readouts (creating execution/timing risk). Overall, the positives — strong sales, upgraded DAYBUE guidance, regulatory wins and a deepening pipeline with imminent binary catalysts — outweigh the operational and timing risks presented.
View all MX:ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 10 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 6 | 0 | 6 |
